ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 627

Zostavax Vaccine Is Safe in Lupus Patients with Low Disease Activity

Eliza F. Chakarvarty1, Joel M. Guthridge2, Joan T. Merrill3, Abigail Cogman2, Tiny Powe1, Virginia C. Roberts4 and Judith A. James5, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis Immunology, OMRF, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Safety, systemic lupus erythematosus (SLE) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:   The Zostavax vaccine was FDA approved in 2006 for the prevention of herpes zoster in healthy adults over age 50.  Because it is a live-attenuated vaccine, concerns exist regarding the safety of vaccination in individuals with autoimmune diseases and those on immunosuppressive therapies.  We sought to evaluate the safety and immunogenicity of Zostavax vaccination in a group of SLE patients compared to healthy control subjects.

Methods:   Ten SLE patients and ten healthy control subjects, all older than 50 years, were recruited to receive Zostavax vaccination followed by 12 weeks of follow-up for safety and immunogenicity.  All study subjects had serologic confirmation of primary varicella infection before vaccination. SLE patients had mild, stable disease, with SLEDAI ≤ 4 at enrollment.  SLE medications were restricted to azathioprine, methotrexate, anti-malarials, and ≤ 10 mg prednisone daily.  Exclusion criteria included history of any varicella vaccination, herpes zoster within 5 years, and use of mycophenolate mofetil, cyclophosphamide or biologic therapies within 6 months of enrollment.

Each subject received Zostavax subcutaneously in the deltoid region during the baseline visit.  Follow-up visits were scheduled at 2, 6, and 12 weeks following vaccination for safety and efficacy assessments.  The primary safety endpoint was development of herpetiform or bullous lesions at the injection site at any time.  Secondary safety endpoints were SLE flare by SLEDAI flare index, any injection site reaction, and any treatment-related adverse events.  Primary immunogenicity endpoint was change in VZV-specific cell mediated immunity at 6 weeks compared to baseline between groups.  Secondary endpoints included changes in WBC subsets by FACs analysis at each time point.

Results:  All study participants were women.  Baseline demographics are outlined in Table 1.Among SLE patients, mean baseline SLEDAI was 1.1 (range 0-2).  Four patients were receiving prednisone (range 2.5-10 mg daily), two, methotrexate, and seven hydroxychloroquine.  All subjects received Zostavax vaccination and have completed at least 6 weeks of follow-up, and 13 have completed the 12 week study.  No episodes of herpes zoster, bulliform lesions at the injection site, serious AEs, or SLE flares occurred during the study.  Three subjects in each group experienced injection site reactions of erythema or tenderness.  All were mild and transient.  Mean change in SLEDAI score at six weeks was 0.2. Proportions of leukocyte subsets or plasmacytoid dendritic cells were not significantly changed following vaccination in either group. Functional varicella response cellular assays will be performed on batched samples once all 12-week visits have been completed.

Conclusion:   Zostavax vaccination appears to be well tolerated in this cohort of patients with mild SLE on mild to moderate immunosuppressive therapy.

Table 1:  Demographic and Safety Outcomes

SLE

Healthy

n

10

10

Age,  mean (SD)

60.5 (5.4)

55.3 (4.2)

European American

7

7

African American

3

3

h/o shingles

4

2

Taking prednisone

4

 –

  mean daily dose

6.9 mg

 –

Taking HCQ

7

 –

Taking MTX

2

 –

Baseline SLEDAI

1.1 (0.99)

 –

 

 

 

ISR (any), n

3

3

  Erythema, tenderness

3

3

  Vesicular

0

0

6 week SLEDAI

1.3 (1.2)

 –

mean Δ SLEDAI

0.2 (1.5)

 –

SLE flare

0

 –


Disclosure:

E. F. Chakarvarty,
None;

J. M. Guthridge,
None;

J. T. Merrill,
None;

A. Cogman,
None;

T. Powe,
None;

V. C. Roberts,
None;

J. A. James,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/zostavax-vaccine-is-safe-in-lupus-patients-with-low-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology